Evidence map›Paper›PMID 42889396›Full record

ArticleFrontiers in radiology2026

Effect of metformin treatment on brain 18F-FDG uptake: a translational study.

Rubén Fernández de la Rosa, Gonzalo Cuesta Domingo, Pedro Nespral, Elena Marcos-Macías, Marta Vaillant, Luis García-García, Miguel Ángel Pozo, Jordi A Matias-Guiu, María Nieves Cabrera-Martin, Mirjam Brackhan and 1 more

Abstract read
In one paragraph

Article in Frontiers in radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rubén Fernández de la Rosa *Cartografía Cerebral, Hospital Clínico San Carlos, IdISSC, Madrid, Spain.
Gonzalo Cuesta Domingo *Nuclear Medicine Department, Hospital Clínico San Carlos, IdISSC, Madrid, Spain.
Pedro NespralNuclear Medicine Department, Hospital Clínico San Carlos, IdISSC, Madrid, Spain.
Elena Marcos-MacíasCartografía Cerebral, Hospital Clínico San Carlos, IdISSC, Madrid, Spain.
Marta VaillantNuclear Medicine Department, Hospital Clínico San Carlos, IdISSC, Madrid, Spain.
Luis García-GarcíaCartografía Cerebral, Hospital Clínico San Carlos, IdISSC, Madrid, Spain.
Miguel Ángel PozoCartografía Cerebral, Hospital Clínico San Carlos, IdISSC, Madrid, Spain.
Jordi A Matias-GuiuNeurology Department, Hospital Clínico San Carlos, IdISSC, Madrid, Spain.
María Nieves Cabrera-MartinNuclear Medicine Department, Hospital Clínico San Carlos, IdISSC, Madrid, Spain.
Mirjam Brackhan *Cartografía Cerebral, Hospital Clínico San Carlos, IdISSC, Madrid, Spain.
Pablo Bascuñana *Cartografía Cerebral, Hospital Clínico San Carlos, IdISSC, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Metformin is one of the most widely used drugs to control diabetes type 2. However, there is no indication of pausing metformin treatment before an Methods: Results: In mice, acute treatment induced a significant hypermetabolism in several brain regions including hippocampus (1.07 ± 0.07 vs 0.94 ± 0.08; Discussion: Our results show that metformin treatment might modify

Indexed as

diabetesmetforminneurodegenerationneuroimagingPET

Identifiers

PMID42889396
PMCPMC13669182

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.